➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
Medtronic
Merck
McKinsey
Johnson and Johnson
Express Scripts

Last Updated: September 21, 2021

DrugPatentWatch Database Preview

Claims for Patent: 9,216,179


Email this page to a colleague

« Back to Dashboard

Summary for Patent: 9,216,179
Title:Treatment of gout and hyperuricemia
Abstract: Sodium 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylt- hio)acetate is described. In addition, pharmaceutical compositions and uses of such compositions for the treatment of a variety of diseases and conditions are described.
Inventor(s): Miner; Jeffrey (San Diego, CA), Girardet; Jean-Luc (San Diego, CA), Quart; Barry D. (Encinitas, CA)
Assignee: ARDEA BIOSCIENCES, INC. (San Diego, CA)
Application Number:13/704,192
Patent Claims: 1. A method of reducing serum uric acid levels, treating hyperuricemia, or treating gout in a human comprising co-administration of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)ace- tate, or a pharmaceutically acceptable salt thereof, and allopurinol to the human, wherein said method provides serum urate levels of less than 6 mg/dL; and wherein said method results in an adverse event in less than 15% of the humans.

2. A method of reducing serum uric acid levels, treating hyperuricemia, or treating gout in a human comprising co-administration of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)ace- tate, or a pharmaceutically acceptable salt thereof, and allopurinol to the human, wherein the serum urate levels are less than 4 mg/dL.

3. A method of reducing serum uric acid levels, treating hyperuricemia, or treating gout in a human comprising co-administration of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)ace- tate, or a pharmaceutically acceptable salt thereof, and allopurinol to the human, wherein said method provides serum urate levels of less than 6 mg/dL; and wherein the method provides a serum urate levels intraday change from baseline of more than 50%.

4. A method of reducing serum uric acid levels, treating hyperuricemia, or treating gout in a human comprising co-administration of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)ace- tate, or a pharmaceutically acceptable salt thereof, and allopurinol to the human, wherein said method provides serum urate levels of less than 6 mg/dL, wherein the gout in the human is characterized by the presence of large accumulated deposits of uric acid or tophi.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Baxter
Medtronic
Harvard Business School
Moodys
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.